Vazzano added that cash projections neither account for sales ... It is likely, therefore, that at least part of the funds raised from the voucher sale will go towards the gene therapy’s launch.

Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher ...

With the PRV sale, the company has "sufficient cash for more than two years of operating ... In November, PTC Therapeutics sold a voucher for $150 million, again without disclosing the buyer's ...

but the biotech can console itself by counting the cash from the sale of its priority review voucher (PRV). The company received the rare pediatric disease PRV from the FDA two weeks ago as part ...

Combined with the cash proceeds of $148.3 million, net of fees, from the sale of the PRV after the end of the quarter, cash, cash equivalents and investments would be $217.0 million. About Zevra ...

The company’s cash position at the end of the third quarter was about $565 million. The company said proceeds from the voucher sale will support commercial operations, R&D programs in central ...

US-based Abeona Therapeutics has signed a deal to sell its priority review voucher for $155m, two weeks after picking up approval in the US for its first commercial product. The biotech company ...

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash ...